OBJECTIVE: To optimize the type and matching of faropenem（ FP） and biexpenem（ BP） combined with lactamase inhibitors

so as to screen out the composition with the strongest anti-tuberculous activity. METHODS:The microplate alamar blue assay（ MABA） was adopted to determine the type and matching of FP and BP combined with lactamase inhibitors by measuring the minimum inhibitory concentration（ MIC） of mycobacterium tuberculosis standard strain H37 Rv

and the anti-tuberculosis activity of the drug combinations was verified by clinical isolated strains; the MIC of drug combination in two-drug combinations with six anti-tuberculous drugs were determined by MABA method

and the in vitro drug interactions was evaluated by calculating the fractionated inhibition concentration（ FIC）. RESULTS: The MIC of FP and BP combined with potassium clavulanate（ CLV） in fixed CLV concentration of2. 5 μg/ml against H37 Rv were respectively 2 μg/ml and 1 μg/ml; for the MIC of clinical isolated strains

the FP/CLV were 2-4 times lower than FP in 88% of strains

and the BP/CLV were 4-8 times lower than BP in 92% of strains; FP/CLV was synergistic with sodium aminosalicylate and protionamide

BP/CLV was synergistic with capromycin

sodium aminosalicylate and protionamide

BP/CLV was partially synergistic with linezolid and levofloxacin

BP/CLV and clofazimine had additive effect

and other combinations were unrelated. CONCLUSIONS:FP/CLV and BP/CLV have good anti-tuberculous activity

BP/CLV is more active and has a good combination with commonly used second-line anti-tuberculous drugs.